This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

Takeda is walking away from the last target in a collaboration with Wave Life Scien | Takeda has brandished a termination ...

Wave Life Sciences (NASDAQ:WVE) said Takeda (NYSE:TAK) has elected not to exercise its option to further develop its ...

Takeda Pharmaceutical offers a strong cash position and an above-average dividend yield. Find out why I'm bullish on TAK ...

There is no simple solution to tackling health inequity, but we’re confident that infusing health equity principles across ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

Loh led a Willenken team that won a $505.6 million award for AbbVie Pharmaceuticals in a breach-of-contract dispute with ...

Pharmaceutical company Lupin has announced a non-exclusive patent licence agreement with Takeda Pharmaceutical for the ...

Takeda, a global pharmaceutical leader, is celebrating a decade in Vietnam, emphasizing its commitment to improving ...